FUN heads into the final stretch of its peak season carrying a 26% one-month loss, nearly 20% of its float sold short, and a set of analysts who just trimmed targets for the third time in six weeks — the setup is as uncomfortable as any in consumer discretionary right now.
The short positioning here is not subtle. Short interest runs at 19.2% of the free float, a level that places FUN in the 95th percentile on ORTEX's short score ranking (factor score of 5, meaning only 5% of the universe carries heavier short conviction). The ORTEX short score itself holds at 73.5 — elevated and sticky, barely moving over the past two weeks despite the stock's continued slide. Borrow conditions are looser than the headline short interest implies: availability runs near 191%, meaning there is roughly twice as much supply in the lending pool as there are shares already borrowed. Cost to borrow is a negligible 0.45%, fractionally above last week but still well inside the "easy borrow" range. In other words, shorts are heavily positioned but face no meaningful squeeze pressure — the borrow market gives them no urgency to cover. Options traders have nudged in the same direction. The put/call ratio ticked up to 0.78 this week, running about 1.7 standard deviations above its 20-day average of 0.74, the most defensive options positioning FUN has seen in this stretch. Neither signal is at an extreme, but both point the same way.
The analyst community has done nothing to arrest the slide — and in fact accelerated the target resets. Every firm that commented after the August earnings print cut its price target. Truist, JP Morgan, Barclays, Oppenheimer, and Citizens all reduced targets, most landing in the $22–$24 range, though ratings were universally held. JP Morgan's Neutral at $22 and Truist's Buy at $22 tell you something important: even the most optimistic voices now see a stock worth roughly 79% more than where it trades ($12.30), yet none have converted that theoretical upside into a more aggressive stance. The consensus mean target of $20.69 implies around 68% implied return potential — a number that usually signals either a deeply mispriced stock or a market that does not trust the numbers. The bear case gives you a clue: a leverage ratio of 5.5x expected to climb toward 5.9x, earnings that missed badly last quarter (the stock fell 12.7% the day results landed in August and shed another 11% over the following week), and the structural problem that the company's EBITDA multiple math only gets you near $29 by 2027 under conservative assumptions. EV/EBITDA sits at 8.1x, not egregiously stretched, but the PE is deeply negative and EPS momentum scores are scraping the bottom of the universe (2nd percentile over 30 days, 1st percentile over 90 days). The bull case rests on a new CEO, cost discipline, and the thesis that season pass economics stabilise attendance — but those are promises, and the August print made investors reluctant to price them in.
The ownership picture adds one genuinely newsworthy fact: Rehan Jaffer filed a Schedule 13D/A in April 2025, which is the activist flag, and as of June this year held a 4.98% stake. A 13D filer means disclosed activist intent — this is not a passive position. The institutional register is otherwise dominated by BlackRock at 15.6% (and still adding in August), with Darlington Partners trimming from 8.5% to 7.5% and The Vanguard Group's original 13G position now showing zero shares in a March 2026 filing, though a separate Vanguard Portfolio Management entity filed a 5.1% position in April. The picture on the right is that the index money is stable-to-building, a couple of value-oriented managers have sat still, and the activist has not publicly pushed for anything visible. Stakes disclosed under 13D/G rules are as last filed; a holder dropping below 5% may exit without a further disclosure. The CEO made a modest open-market purchase of ~$248k in August under a 10b5-1 plan — notable for the signal but limited in dollar conviction, and the pre-arranged plan reduces its interpretive weight. Equity awards to the CFO and C-suite in late July and June complete the insider picture: compensation grants rather than discretionary buying.
The next earnings date is November 5. After a quarter that produced a 12.7% single-day drop — the steepest reaction in recent history — and a further five-day drift of negative 11%, investors will want to see whether the new management team is actually bending the cost curve and whether attendance trends improved through the fall season. With shorts entrenched but comfortable, the borrow market offering no pressure toward a cover, and analysts unwilling to push their ratings higher despite targets that imply double-digit percentage upside, the November print becomes a binary moment: confirmation that the cost story is real, or another reset lower.
See the live data behind this article on ORTEX.
Open FUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
